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Abstract
Over the last 40 yr, the majority of research on glucans has focused on b-(1!3)-glucans. Recent studies indicate that
b-(1!6)-glucans may be even more potent immune modulators than b-(1!3)-glucans. Mechanisms by which b-(1!6)glucans are recognized and modulate immunity are unknown. In this study, we examined the interaction of purified
water-soluble b-(1!6)-glucans with macrophage cell lines and primary peritoneal macrophages and the cellular and
molecular consequences of this interaction. Our results indicate the existence of a specific b-(1!6)-glucan receptor that
internalizes the glucan ligand via a clathrin-dependent mechanism. We show that the known b-(1!3)-glucans receptors
are not responsible for b-(1!6)-glucan recognition and interaction. The receptor–ligand uptake/interaction has an
apparent dissociation constant (KD) of 4 mM, and was associated with phosphorylation of ERK and JNK but not
IkB-a or p38. Our results indicate that macrophage interaction with b-(1!6)-glucans may lead to modulation of
genes associated with anti-fungal immunity and recruitment/activation of neutrophils. In summary, we show that macrophages specifically bind and internalize b-(1!6)-glucans followed by activation of intracellular signaling and modulation of
anti-fungal immune response-related gene regulation. Thus, we conclude that the interaction between innate immunity
and b-(1!6)-glucans may play an important role in shaping the anti-fungal immune response.
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Introduction
Glucans are structurally diverse fungal biopolymers
that stimulate innate immunity.1–3 Fungal b-(1!3)glucans are generally recognized as important PAMPs
in the anti-fungal immune response.4–6 The binding of
b-(1!3)-glucans by speciﬁc receptors results in activation of anti-fungal innate and adaptive immune
responses,3,7–13 leading to eﬀects of b-(1!3)-glucans
as immune modulators.14–17 Over the last 40 yr, the
vast majority of research on glucans has focused on
b-(1!3)-glucans.1–16 However, there are glucans
other than b-(1!3)-linked glucans present in the
fungal cell wall, although they are generally present at
lower levels.18,19 Recent studies suggest that b-(1!6)glucans may be even more potent immune modulators
than b-(1!3)-glucans.20–23 Compared with b-(1!3)glucans, the b-(1!6)-glucans elicit a more potent
induction of IL-1b, IL-6, IL-8 and TNF-a in human
whole blood in vitro.23 Abs directed against b-(1!6)glucan have been detected in human sera, and the

human Ab response to b-(1!6)-glucan was greater
than that observed for b-(1!3)-glucan.21,22 In addition, when compared with beads coated with b(1!3)-glucans, a more eﬃcient internalization of
beads coated with b-(1!6)-glucans by neutrophils
has been reported.20
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Activation of transcription factors induced by the
interaction of b-(1!3)-glucans with immune cells,3,24
as well as up- and/or down-regulation of speciﬁc
mRNAs,25,26 has been described previously. It is reasonable to speculate that the reported cytokine induction and Ab responses to b-(1!6)-glucans would be
preceded by activation of transcription factors and
changes in mRNA levels;21–23 however, these changes
in cellular and molecular function have not yet been
investigated for pure b-(1!6)-glucans.
Dectin-1 has been identiﬁed as the principal pattern
recognition receptor for b-(1!3)-glucans,8,27 and is
expressed on monocytes, macrophages, dendritic cells
and neutrophils.27,28 Adams et al. and Palma et al. have
reported that Dectin-1 does not recognize b-(1!6)-glucans.7,29 This suggests that there is another receptor
that mediates responses to b-(1!6)-glucan. There are
three other receptors that have been reported to bind b(1!3)-glucans: the type 3 complement receptor
(CR3),10,30 scavenger receptor A (SRA) and a lactosylceramide,9,11 although these receptors bind b-(1!3)glucans less selectively than Dectin-1. Zimmermann
et al. have reported that lactosylceramide does not
bind b-(1!6)-glucans.11 However, CR3 and SRA
have not been evaluated for their ability to interact
with b-(1!6)-glucans. Thus, the mechanisms by
which b-(1!6)-glucans are recognized and modulate
immunity in humans and animals are unknown.
In this study, we investigated the mechanisms associated with the induction of biological activities in
macrophages by b-(1!6)-glucans. By employing
macrophage cell lines and peritoneal macrophages
derived from wild type (WT), Dectin-1 (Dectin-1/),
SRA/ or CR3/) knockout mice, we explored the
recognition and binding speciﬁcity of b-(1!6)-glucans
by macrophages and what, if any, role known b-(1!3)glucan receptors may play in this interaction.
Additionally, we examined the binding characteristics
and mechanisms of internalization of b-(1!6)-glucans
by macrophages, as well as the activation of transcription factors and modulation of gene transcription following the interaction between b-(1!6)-glucans and
macrophages.

Materials and methods
Ethics statement
All animal procedures were conducted in strict compliance with the National Institutes of Health’s Guide for
the Care and Use of Laboratory Animals. The animal
protocol was reviewed and approved (protocol number
101201) by the University Committee on Animal Care
at the James H. Quillen College of Medicine, East
Tennessee State University (ETSU), under the guidelines of the Association for Assessment and
Accreditation of Laboratory Animal Care, US
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Department of Agriculture, and the Public Health
Service guidelines for the care and use of animals as
attested by the National Institutes of Health. All eﬀorts
were made to minimize suﬀering.

Reagents
Alexa Fluor 647 (AF647), propidium iodide and a
Vybrant Lipid Raft Labeling Kit were purchased
from Molecular Probes (Eugene, OR, USA). DMSO,
methyl-b-cyclodextrin, chlorpromazine, nystatin, cytochalasin D and hypotonic sucrose were purchased from
Sigma Chemical (St. Louis, MO, USA). Wortmannin
was purchased from Alomone laboratories (Jerusalem,
Israel). Cytochalasin D and wortmannin were
pre-dissolved in DMSO and diluted to the stock concentrations in RPMI, while all other inhibitors were
dissolved in serum-free RPMI medium. All stock
solutions were incubated overnight in pre-washed polymyxin-coated agarose beads (BioRad, Hercules, CA,
USA) to remove endotoxin, and ﬁlter sterilized prior
to use.

Polysaccharides
Glucan phosphate, a water-soluble b-(1!3)-glucan,
was extracted from Saccharomyces cerevisiae,31 and
had a molecular mass of 1.5  105 g/mol. Water-soluble
b-(1!6)-glucan was isolated from Malassezia sympodialis as previously described, and had a molecular
mass of 6  104 g/mol.32 The chemical structures of
the glucans used in this study were conﬁrmed by 1HNMR33 and the physicochemical characteristics were
conﬁrmed as described earlier.3,34 The b-(1!6)-glucan
was derivatized with diaminopropane at the reducing
terminus and labeled with AF647 as previously
described.35,36

Macrophage cell lines and isolation of murine
primary macrophages
Human macrophage cell line U-937 (CRL-1593.2),
murine macrophage cell lines J774A.1 (TIB-67) and
RAW 264.7 (TIB-71) were obtained from American
Type Culture Collection (Rockville, MD, USA). Cell
lines were grown either as suspension cultures (U937)
or adherent monolayers (J774A.I and RAW 264.7) at
37 C and 5% CO2 in RPMI 1640 (Cellgro, Manassas,
VA, USA) containing 9% calf serum, 1% FBS and 1%
(v/v) penicillin–streptomycin. Peritoneal macrophages
were elicited using thioglycollate and isolated from
WT, Dectin-1/, SRA/ or CR3/ mice on the
C57BL/6 J background as previously described.36
Dectin-1/ and SRA/ mice were obtained from
breeding colonies in the Department of Laboratory
Animal Resources at ETSU. WT and CR3/ mice
were purchased from the Jackson Laboratory
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(Bar Harbor, ME, USA). The animals were maintained
on standard laboratory chow and water was available
ad libitum with a 12-h light/dark cycle. Serologic testing
conﬁrmed that the mice were virus free. All animal procedures were reviewed and approved by the institutional review board at the James H Quillen College of
Medicine, ETSU.

Flow cytometry
Optimal concentrations for measurements of the ﬂuorescent labeled b-(1!6)-glucan in ﬂow cytometry and
confocal microscopy were identiﬁed in pilot experiments (not shown). Diﬀerent inhibitor concentrations
were tested for their eﬀect on cell viability using
the trypan blue exclusion test (not shown).
Concentrations were selected to maintain cell viability
during treatment. To perform the competition experiments, cells were plated in six-well plates at 3  105 cells
per well and grown for 48 h at 37 C in 5% CO2.
Peritoneal macrophages were counted and seeded at
6  106 cells per well. They were allowed to adhere
overnight (12 h). Before treatment, cells were washed
and fresh medium was added. Cells were pre-incubated
for 30 min with 125 or 500 mg/ml of b-(1!6)-glucan or
b-(1!3)-glucan prior to addition of 10 mg/ml ﬂuorescently labeled b-(1!6)-glucan and incubated for
another 1.5 h. Untreated cells served as negative control
and the positive control only received the 10 mg/ml
ﬂuorescently labeled b-(1!6)-glucan. To investigate
the internalization pathway, cells were pre-treated
with serum-free medium alone (negative and positive control), serum-free medium containing
12.5–50.0 mM
nystatin,
2.5–10.0 mM
methyl-bcyclodextrin, 100–400 nM wortmannin, 5–20 mM cytochalasin D, 10–40 mM chlorpromazine or 100–400 mM
sucrose for 30 min at 37 C. After pre-treatment, 10 mg/
ml of ﬂuorescently labeled b-(1!6)-glucan was added
to each well, except to the negative control, and the
cells were incubated for an additional 1.5 h at 37 C.
For the saturation experiments, WT peritoneal macrophages were counted and seeded at 6  106 cells per
well. They were allowed to adhere overnight. Before
treatment, the cells were washed and fresh medium
was added. Cells were incubated with a dilution series
of non-labeled b-(1!6)-glucan (0.065–8.300 mM) for
30 min before the addition of 10 mg/ml ﬂuorescently
labeled b-(1!6)-glucan. The negative control was left
untreated and a positive control was pre-incubated in
the absence of competitors but 10 mg/ml ﬂuorescently
labeled b-(1!6)-glucan was added. After each experiment, cells were harvested with lidocaine, washed with
PBS and re-suspended in Pharmingen Stain Buﬀer (BD
Biosciences, San Jose, CA, USA). Mean ﬂuorescence
was measured and analyzed using a FACScalibur
ﬂow cytometer with CellQuest software (BD
Biosciences).
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Confocal microscopy
For confocal microscopy, 2.5  105 cells were seeded on
sterile cover slips in a 12-well plate and allowed to grow
for 48 h. If applicable, cells were pre-treated for 30 min
in serum-free medium containing the speciﬁed endocytosis inhibitors before addition of 100 mg/ml ﬂuorescently labeled b-(1!6)-glucan. The negative control
was left untreated and the positive control was preincubated in the absence of inhibitors but did receive
100 mg/ml ﬂuorescently labeled b-(1!6)-glucan. After a
3-h incubation, cover slips were carefully washed with
PBS. To visualize the cell membrane, cells were stained
with the Vybrant Lipid Raft Labeling Kit. After
another washing cycle, cells were ﬁxed with 4% paraformaldehyde. Cover slips were mounted with Prolong
Antifade (Molecular Probes). The slides were imaged
on a Leica DM IRBE inverted microscope with the
Leica TC2 SP2 confocal microscopy system (Leica,
Wetzlar, Germany). The images were analyzed using
Leica confocal software.

Western blots
For protein measurements, J774a.1 cells were cultured
to conﬂuency in T75 ﬂasks. Cells were treated for 15,
30, 60 and 120 min with 100 mg/ml b-(1!6)-glucan.
Untreated cells served as control. After treatment,
cells were incubated for 1 h in lysis buﬀer containing
10 mM Hepes (pH 7.9), 10 mM KCL, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 1 mM
aprotinin, 14 mM leupeptin, 1 mM pepstatin and
80 mg/ml benzamidine, and then lysed by adding 10%
Nonidet P40. Protein concentrations in the cell extracts
were quantiﬁed with the BCA protein assay (Bio-Rad,
Hercules, CA, USA). Fixed amounts of total protein
(100 mg for JNK and 50 mg for ERK, IkB-a and p38)
were resolved by SDS-PAGE and transferred to PVDA
membranes. The membranes were blocked with
Tris-buﬀered saline (TBS) + 0.05% Tween20 + 5%
Milk (TBTM) and incubated with rabbit anti-phospho-ERK, rabbit anti-phospho-JNK, rabbit-anti-phospho-p38 or mouse-anti-phospho-IkB-a (Cell Signaling
Technology. Beverly, MA, USA) overnight. After
washing three times for 10 min in TBTM, membranes
were incubated with the corresponding peroxidase-conjugated anti-mouse or peroxidase-conjugated antirabbit secondary Abs (Cell Signaling Technology).
After washing three times for 10 min in TBS + 0.05%
Tween20, membranes were developed by chemiluminescence (Immun-Star WesternC Chemiluminescent
Kit; Bio-Rad) and then visualized using a GBox
(Syngene). The membranes were washed, re-blocked
and re-probed overnight with the appropriate Ab:
rabbit anti-ERK, rabbit anti-JNK, rabbit anti-p38
and rabbit anti-IkB-a (Santa Cruz Biotechnology,
Inc., CA) followed by incubation with peroxidaseconjugated secondary anti-rabbit Abs (Sigma
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Chemical, MO). Membranes were developed and
imaged as before. Next, membranes were stripped and
re-probed with anti-GAPDH (Biodesign, ME) as loading control, followed by incubation with peroxidaseconjugated secondary anti-mouse Abs (Sigma
Chemical, MO). Membranes were developed by chemiluminescence and visualized using a GBox.

Results

PCR Array

Specific binding and internalization of
-(1!6)-glucan by murine macrophages
Internalization of ﬂuorescently labeled b-(1!6)-glucan
was explored using three diﬀerent macrophage cell lines
to exclude possible artifacts due to one speciﬁc cell line
(Figure 1A). Initially, we employed ﬂow cytometry and
confocal microscopy to conﬁrm that all three cell lines
bound and internalized b-(1!6)-glucan (data not

(A) 120
(1,6)-β-glucan
(1,3)-β-glucan

% Fluorescence
relative to positive control

The PCR array procedure was performed following the
protocol supplied with the RT2 Proﬁler PCR Array
(Qiagen). Brieﬂy, J774a.1 cells were cultured to 80%
conﬂuency in T75 ﬂasks. Cells were treated for 1, 3,
6, 12 and 24 h with 100 mg/ml b-(1!6)-glucan.
Controls were left untreated. Total RNA was extracted
using the RNeasy mini kit (Qiagen) and purity was
controlled using an Agilent Bioanalyzer. The cDNA
was prepared using the RT2 First Strand Kit
(Qiagen), the sample was then mixed with RT2 SYBR
Green Master mix and the real time PCR program was
run according to the manufacturer’s speciﬁcations.

analysis were produced in Sigmaplot 10 (Systat
Software, San Jose, CA, USA), if not otherwise speciﬁed. Figures for the PCR array data were produced in
with GraphPad Prism (GraphPad, La Jolla, CA, USA).

100

All data was corrected for the appropriate negative
controls.
Competition data is presented as the percent ﬂuorescence relative to the ﬂuorescence of the corresponding
positive controls. Receptor binding/uptake versus concentration data were normalized for ﬂuorescence based
on the proportion of total to labeled glucan. Corrected
ﬂuorescence values were ﬁt to a single-site hyperbolic
binding model using nonlinear least squares regression
with GraphPad Prism version 4.00 for Windows
(GraphPad Software, San Diego, CA) to calculate an
apparent KD and Bmax for the receptor binding/uptake
process. Western blot results were analyzed by measuring the ﬂuorescent intensity of the negatives of the
imaged membranes using GeneTools (Syngene,
Frederick, MA, USA). Values were normalized to a
GAPDH loading control before calculating up-regulation of phosphorylation. Up- or down-regulation was
calculated comparing the phospho-protein to the total
protein (fold regulation). All experiments were repeated
at least three times. Groups were compared by
ANOVA applying post-hoc testing using Tukey’s procedure; probability levels of P  0.05 were considered
signiﬁcant.
The PCR array experiment was repeated twice and
analyzed using the Qiagen PCR Array Data Analysis
Web portal. Up- or down-regulation of mRNAs was
calculated by comparing treated samples with non-treated controls (fold regulation). Signiﬁcance for up- or
down-regulation was set to a diﬀerence in fold regulation of at least two. Figures and statistic calculations
for ﬂow cytometry experiments and Western blot

80

*
*

*
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U937

(B) 120
% Fluorescence
compared to positive control

Data analysis

RAW

J774a.1`
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(1,6)-β-glucan
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Figure 1. Specific binding and internalization of b-(1!6)glucan by macrophage cell lines. (A) Human U937 and murine
RAW and J774a.1 cell lines were treated with 50  higher concentration of non-labeled competitors—b-(1!6)-glucan or b(1!3)-glucan—prior to the treatment with 10 mg/ml (167 nM)
labeled b-(1!6)-glucan. (B) J774a.1 cells treated with 12.5or
50  higher concentrations of non-labeled competitors—
b-(1!6)-glucan or b-(1!3)-glucan—prior to the treatment
with 10 mg/ml (167 nM) labeled b-(1!6)-glucan. The data are
presented as the percent fluorescence relative to the fluorescence of the corresponding positive controls  SD of four
repeated measurements per group. *Significant difference
compared with control (P  0.05).
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shown). Once we conﬁrmed that all three cell lines
interacted with the glucan, we examined the speciﬁcity
of this interaction with competition experiments using a
50-fold excess of non-labeled b-(1!6)-glucan or nonlabeled b-(1!3)-glucan (Figure 1A). To demonstrate
concentration dependency we employed a 12.5- and
50-fold excess of non-labeled glucan in J774a.1 cells
(Figure 1B). Speciﬁcity of the interaction between the
macrophage cell lines with b-(1!6)-glucan was clearly
demonstrated. A signiﬁcant reduction in binding/
internalization of 20–30% was observed for the
higher concentration (500 mg) of non-labeled b-(1!6)glucan (Figure 1A). The 125 mg competitor concentration of b-(1!6)-glucan inhibited the interaction with
macrophages by 10–20% (Figure 1B). In contrast,
non-labeled b-(1!3)-glucan did not inhibit the interaction of labeled b-(1!6)-glucan with the macrophages. Interestingly, the lower concentration (125 mg/
ml) of b-(1!3)-glucan, when used as a competitor,
seems to augment the binding/internalization of labeled
b-(1!6)-glucan (Figure 1B).

Uptake of -(1!6)-glucan macrophages is not
mediated by Dectin-1, SRA or CR3

% Fluorescence compared to positive control

In order to investigate whether the binding and internalization of b-(1!6)-glucan is dependent on one of the
previously reported b-(1!3)-glucan receptors,9–11,30 we
harvested peritoneal macrophages from mice that
are genetically deﬁcient for the respective receptors
(Figure 2). The results of the competition experiments
using primary macrophages were more dramatic
than those observed in cell lines, but similar trends

120
(1,6)-β-glucan
(1,3)-β-glucan
100

80

60

*
*
*

*

40

20
Wild type Dectin-1 –/–

SRA –/–

CR3 –/–

Figure 2. Specific binding and internalization of b-(1!6)glucan by murine primary macrophages. Macrophages were
treated with unlabeled competitors—b-(1!6)-glucan or (b(1!3)-glucan—prior to the treatment with labeled b-(1!6)glucan. The data are presented as the percent fluorescence
relative to the fluorescence of the corresponding positive
controls  SD of four repeated measurements per group.
*Significant difference compared with controls without
competitor (P  0.05).

were observed. A 50-fold excess of non-labeled
b-(1!6)-glucan reduced the binding/internalization of
labeled b-(1!6)-glucan by 50–60% (P < 0.05) in thioglycollate-induced macrophages derived from all the mice
strains employed (Figure 2). Thus, primary macrophages
derived from WT and receptor knockout mice produced
similar results, indicating that the receptors investigated,
that is, Dectin-1, SRA or CR3, do not participate
in the binding or internalization of b-(1!6)-glucan.

-(1!6)-Glucan is internalized by macrophages
via a clathrin-dependent endocytosis mechanism
As we could demonstrate speciﬁc binding and internalization of b-(1!6)-glucan by monocytes/macrophages,
we investigated the mechanisms of b-(1!6)-glucan
internalization. We treated cells with two known inhibitors of each of three distinct internalization pathways:
the lipid raft-mediated endocytosis pathway, phagocytosis and clathrin-mediated endocytosis. Quantitative
changes in binding and internalization of ﬂuorescently
labeled b-(1!6)-glucan were analyzed using ﬂow cytometry (Figure 3A). Inhibitors of lipid raft-mediated
endocytosis, nystatin and methyl-b-cyclodextrin did
not inhibit binding and/or internalization of the
b-(1!6)-glucan. Wortmannin, a phagocytosis inhibitor, did not show signiﬁcant inhibition; however, cytochalasin D at 20 mM signiﬁcantly inhibited binding and
internalization of b-(1!6)-glucan by 20–40%.
Inhibitors of clathrin-mediated endocytosis showed
the most dramatic eﬀect by signiﬁcantly inhibiting
binding and internalization of b-(1!6)-glucan.
Chlorpromazine (40 mM) inhibited glucan uptake by
20–40%, while hypotonic sucrose (100 mM) inhibited
internalization of b-(1!6)-glucan by 25–45% and by
80% at 400 mM. We conﬁrmed these observations
qualitatively using suitable inhibitors and confocal
microscopy (Figure 3B). In agreement with the ﬂow
cytometry data, methyl-b-cyclodextrin and wortmannin
did not inhibit the binding/internalization of the ﬂuorescently labeled b-(1!6)-glucan, while chlorpromazine
treatment clearly reduced bound/internalized ﬂuorescently labeled b-(1!6)-glucan.

-(1!6)-Glucan binds to murine peritoneal
macrophages in a saturable, dose-dependent
manner
Our results strongly indicate a receptor-mediated binding and internalization of b-(1!6)-glucan, which
occurs in a speciﬁc manner. While we have not yet
identiﬁed the receptor, we investigated the binding kinetics of the interaction between b-(1!6)-glucan and its
putative receptor in murine primary peritoneal macrophages. Using a single site-speciﬁc binding model, ﬁtting combined saturation and competitive displacement
data yielded an apparent dissociation constant (KD) of

764

Innate Immunity 21(7)

Figure 3. Internalization of b-(1!6)-glucan by macrophages is mediated via a clathrin-dependent mechanism. Various inhibitors
specific for the different pathways were used. (A) Data as measured by flow cytometry. The data are presented as the percent
fluorescence relative to the fluorescence of the corresponding positive controls  SD of four repeated measurements per group.
(B) Data as measured by confocal microscopy. *Significant difference compared with controls without competitor (P  0.05).

4 mM [95% conﬁdence interval (CI) 2.5–5.0 mM) and a
maximum ﬂuorescence (Bmax) of 61 ﬂuorescence units
(FU)/cell (95% CI 50.0–71.0 FU/cell) (Figure 4).

-(1!6)-Glucan activates the MAPKs, ERK and JNK
but not p38 or NF-B
To investigate possible activation of signal transduction, we measured IkB-a phosphorylation as an index

of NF-kB activation and the phosphorylation of the
MAPKs ERK, JNK or p38 in b-(1!6)-glucan-treated
J774a.1 cells (Figure 5A, B). Phosphorylation was signiﬁcantly up-regulated at 15 min (15  higher than
control) and 30 min (3  higher than control) for
ERK and at 15 min (2  higher than control) for
JNK (Figure 5B). There was no signiﬁcant diﬀerence
in phosphorylation status of p38 or IkB-a in
the J774a.1-treated cells when compared with the

Noss et al.
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Figure 4. Saturability and dose dependence of b-(1!6)-glucan
in primary macrophages. Data from three replicate experiments
were fitted to a single-site hyperbolic binding model using
nonlinear least squares regression. Combined saturation and
competitive displacement data yielded a KD of 4 mM and a Bmax
of 61.

non-treated control at any time point. In peritoneal
macrophages (Figure 6), we observed a similar up-regulation of ERK, although the kinetics of the response
was diﬀerent in that peak activity was observed at
60 min, as opposed to 15 min (Figure 5). As seen in
the J774a.1 cells, p38 and IkB-a showed no change.
We were not able to detect total or phosphorylated
JNK in primary peritoneal macrophages at any time
point in the primary cells.

Macrophage activation by -(1!6)-glucan results in
modulation of genes specific for anti-fungal immune
responses
The activation of a signal transduction cascade leads to
changes in transcription factor activity and induces
changes in gene transcription, that is, mRNA levels.
We used PCR array technology to measure changes
in mRNA levels of genes important for anti-fungal
immune responses in J774a.1 cells after treatment
with b-(1!6)-glucan at diﬀerent time points
(Figure 7A, B). J774a.1 cells were treated with
b-(1!6)-glucan for 1, 3, 6, 12, and 24 h. Three
mRNAs were signiﬁcantly up-regulated ( 4 ) at various time points: C-X-C motif chemokine 10 (Cxcl10),
complement component 5a receptor 1 (C5ar1) and
coagulation factor III (F3). Ten mRNAs were signiﬁcantly down-regulated [ 4  s: prostaglandin-endoperoxide synthase 2 (Ptgs2), IL-1b (Il1), Il23, Il6, IL-1
receptor type 1 (Il1r1), CD83, transcription factor Fos,
C-C motif chemokine receptors type 1 and 5 (Ccr1,
Ccr5) and chemokine C-X-C motif ligand 3 (Cxcl3)].
Fcgr1 and CD40 were down-regulated (2–3-fold), while
Tnf, Pycard, Socs3, Ptpn6, Scarf1, Csf2 and Csf3 were
up-regulated 2–3-fold.

We hypothesized that b-(1!6)-glucans are recognized
by (an) as yet unidentiﬁed receptor(s) in the mammalian innate immune system and that this interaction will
lead to modulation of innate immunity. Using human
and mouse macrophage cell lines we observed that
unlabeled b-(1!6)-glucan, but not b-(1!3)-glucan,
competed for binding/internalization with labeled
b-(1!6)-glucan. This indicates a speciﬁc interaction
between the macrophages and b-(1!6)-glucan.
The apparent augmentation of the binding/internalization of labeled b-(1!6)-glucan by 125 mg/ml of
b-(1!3)-glucan, when used as a competitor, may
point to a dynamic interplay between the diﬀerent
glucan types at certain concentrations and needs further investigation.
Employing peritoneal macrophages derived from
WT, Dectin-1/, SRA/ or CR3/ mice, we found
that non-labeled b-(1!6)-glucan inhibited the binding/
internalization of labeled b-(1!6)-glucan in macrophages from all of the mouse strains. The results were
comparable between WT, Dectin-1, SRA and CR3
knockout mice, demonstrating that the binding/internalization of b-(1!6)-glucan is not inﬂuenced by any of
the known b-(1!3)-glucan receptors. These data are in
line with the previous reports that Dectin-1 does not
bind b-(1!6)-glucan.7,29 In addition, our data extend
these observations to demonstrate that b-(1!6)-glucan
is not bound by SRA or CR3.
The uptake of glucans may occur via phagocytosis,37,38 caveolae/lipid raft-mediated endocytosis,39
which utilizes lipid rafts enriched in sphingolipids
such as lactosylceramide,40 or via clathrin-mediated
endocytosis, a pathway by which many receptorbound ligands are internalized.41 As inhibitors of
these pathways have been shown to sometimes induce
diverse eﬀects on the cells, leading to faulty conclusions,42 we used two structurally dissimilar inhibitors
for each pathway. Inhibiting lipid raft-mediated endocytosis did not aﬀect b-(1!6)-glucan uptake. This is
supported by the results of Zimmermann et al.,11
which show that lactosylceramide, commonly found
in lipid rafts, does not interact with b-(1!6)-glucan.
Of the phagocytosis inhibitors, wortmannin inhibiting
PI3K did not interfere with internalization of b-(1!6)glucan.42 However, cytochalasin D, a blocker of actin
polymerization,42 and both inhibitors of clathrinmediated uptake abrogated b-(1!6)-glucan internalization. As actin polymerization is necessary
for clathrin-mediated endocytosis,43 the inhibition
of b-(1!6)-glucan internalization by cytochalasin
D is consistent with the clathrin inhibition data.
We conclude that the majority of b-(1!6)-glucan is
internalized via clathrin-mediated endocytosis.
We
explored
the
binding
kinetics
of
ﬂuorescently labeled b-(1!6)-glucan and primary
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Figure 5. Effect of b-(1!6)-glucan on phosphorylation of IkB-a, ERK, JNK and p38 in murine macrophage cell line J774a.1.
(A) Representative results of membranes being probed for phosphorylated protein, re-probed for total protein, stripped and
re-probed for loading control. (B) Fold regulation (ratio phosphorylated to total protein) of phosphorylation status of the measured
proteins at different time points. Data are expressed as the ratio of phospho-protein to total protein (fold regulation)  SD of three
repeated measurements. *Significant difference when compared with non-treated control (P  0.05).

murine macrophages. The results yielded an apparent
KD of 4 mM and a Bmax of 61 FU/cell. A KD of
4 mM is rather high and indicates a low aﬃnity for
the ligand. Compared with the KD of 24 mM reported
for b-(1!3)-glucans using a similar experimental
design,44 the measured KD for b-(1!6)-glucan is
lower. Also, Kougias et al.,35 who used ﬂuorescently
labeled glucans, reported a KD of 5.6 mM for b(1!3)-glucan binding to macrophage membranes.
Thus, the rather high KD value measured in the present

study for b-(1!6)-glucan binding is comparable with
the high KD value for receptor binding of b-(1!3)-glucans, which have been generally accepted as important
fungal PAMPs.4–6
We investigated the phosphorylation of IkB-a, as a
marker for NF-kB activation, and the activation of
MAPKs, including ERK, JNK and p38, as these signaling pathways have been reported to be activated by
some b-(1!3)-glucans and fungi.24,45 Using the macrophage cell line J774a.1, we found that ERK and JNK
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Figure 6. Phosphorylation status of IkB-a, ERK and p38 in
primary peritoneal macrophages treated with b-(1!6)-glucan.
The data are presented as fold regulation (ratio of phosphorylated to total protein) of phosphorylation status of the measured
proteins at different time points. Data are expressed as the ratio
of phospho-protein to total protein (fold regulation)  SD of
three repeated measurements. *Significant difference when
compared with non-treated control (P  0.05).

phosphorylation were signiﬁcantly up-regulated, while
IkB-a and p38 did not show a change in phosphorylation status. Primary macrophages showed similar
results for phosphorylation status of ERK, although
ERK phosphorylation kinetics were delayed when compared with the J774a.1 cells. For b-(1!3)-glucans, activation of NF-kB has generally been reported;24,46 thus,
our results suggest that b-(1!6)-glucans activate diﬀerent signal transduction pathways than those reported
for b-(1!3)-glucans.
Analyzing the eﬀect of b-(1!6)-glucans on modulation of gene transcription using a commercial PCR

array led to the observation that after b-(1!6)-glucan
interaction with macrophages, generally more genes
were down-regulated than were up-regulated. The
mRNAs for the inﬂammatory mediators IL-1b, IL-6,
PTGS2 and IL-1R1 were down-regulated, while the
mRNAs for inﬂammatory mediators TNF-a,
PYCARD, SOCS3 and F3 were up-regulated. These
changes in the mRNA proﬁle suggest a speciﬁc
immune response, as opposed to general inﬂammation.
Rand et al. measured gene regulation in alveolar
macrophages,26 and Hida et al. in splenocytes,25 after
treatment with b-(1!3)-glucans. Both studies found an
up-regulation of IL-1b and IL-6 mRNAs, while in our
study we found that these mRNAs were down-regulated by b-(1!6)-glucan. We did not examine the
protein levels of cytokines in this study; however,
future investigations should include cytokine expression, as a strong induction of pro-inﬂammatory
cytokine production by b-(1!6)-glucans has been
reported in human whole blood.23
In this study, Cxcl10, C5ar1, Csf2 and Csf3 mRNAs
were up-regulated in macrophages treated with b(1!6)-glucan. These genes code for chemotactic proteins that interact with granulocytes.47,48 In contrast,
Cxcl3, Ccr1 and Ccr5 mRNAs, which code for proteins
responsible for chemotaxis of leukocytes and especially
monocytes, were down-regulated by b-(1!6)-glucan.
These results indicate that b-(1!6)-glucans induce a
macrophage response that may result in activation
and recruitment of neutrophilic granulocytes. This is
in line with the results of Rubin-Bejerano et al.,20
who reported that b-(1!6)-glucans coated onto beads
eﬃciently mediated neutrophil activity.
The identiﬁcation of receptors responsible for recognition and response to fungal pathogens is essential to
understanding the mechanisms by which innate immunity responds to these microbes. Our results strongly
indicate the existence of a speciﬁc receptor for
b-(1!6)-glucans on macrophages. Our data exclude
several known b-(1!3)-glucan receptors as putative
b-(1!6)-glucan receptors. However, thus far, the
putative receptor remains unidentiﬁed. Nevertheless,
the b-(1!6)-glucan interaction with a speciﬁc receptor
may play an important role in the anti-fungal
immune response. Indeed, many studies have
reported the importance of the b-(1!6)-glucan side
chains in b-(1!3)-glucan bioactivity.49,50 In the current
study, we employed a pure b-(1!6)-glucan. Its bioactivity is clearly diﬀerent from pure b-(1!3)-glucans
in activation of transcription factors and regulation
of mRNAs. The results indicate the induction of a
speciﬁc immune response leading to activation
and recruitment of neutrophilic granulocytes by
b-(1!6)-glucan. This suggests that b-(1!6)-glucan
may be an important fungal PAMP that may play a
distinct and novel role in shaping the anti-fungal
immune response.
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Figure 7. Treatment of the macrophage cell line J774a.1 with b-(1!6)-glucan results in (A) up- or (B) down-regulation of mRNAs
associated with anti-fungal immune responses. Data are expressed as the ratio of treated samples to non-treated controls (fold
regulation) of two repeated measurements. *Significance based on  two-fold changes; **significance based on  four-fold changes as
suggested by the manufacturer.
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